Skip to content
DataLookout
Menu

NACxosNCT07939841

N-Acetylcysteine (NAC) in Primary Sclerosing Cholangitis (PSC)

StatusNot Yet Recruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Percentage Change in Serum Alkaline Phosphatase (ALP)
Timeframe: Baseline and Week 16

Secondary (3)

Longitudinal Change in Aspartate Aminotransferase (AST)
Longitudinal Change in Alanine Aminotransferase (ALT)
Longitudinal Change in Gamma-Glutamyl Transferase (GGT)

Arms and interventions

N-Acetylcysteine (NAC) TreatmentExperimental

Participants will receive oral N-acetylcysteine (NAC) at a dose of 600 mg twice daily (1,200 mg/day) for the first 12 weeks. At Week 12, participants with a reduction in alkaline phosphatase (ALP) of at least 40% from baseline will continue at 1,200 mg/day, while those with less than a 40% reduction will increase to 1,800 mg/day through Week 16. Participants achieving at least a 50% reduction in ALP at Week 16 may continue treatment through Week 20, according to the study protocol.

Drugs: N-Acetylcysteine (NAC) Treatment

Sites

1 site in 1 country

  • Brigham and Women's HospitalBoston, Massachusetts, United States